Citi analyst Thomas Palmer lowered the firm’s price target on Archer Daniels to $63 from $64 and keeps a Neutral rating on the shares ahead of the Q2 report. The firm models earnings in line with the consensus, with potential upside in Other and Carbohydrate Solutions offset by downside risk in Nutrition. The analyst thinks an annual guidance reiteration is more likely than an adjustment, with the recent upward move in crush margins, offsetting downside risk to the Nutrition outlook.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADM:
- Archer Daniels, LG Chem lactic and polylactic acid projects to not move forward
- Archer Daniels Midland Appoints New EVP and CFO
- Archer Daniels appoints Monish Patolawala as CFO
- Archer Daniels, Bayer extend farming collaboration
- Archer Daniels lied about stake in Xinjiang factories, Hunterbrook Media reports